• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Scorpion Therapeutics Appoints Saurabh Saha, M.D., Ph.D. to its Board of Directors

    4/4/22 8:00:00 AM ET
    $CNTA
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNTA alert in real time by email

    Scorpion Therapeutics, Inc. ("Scorpion Therapeutics"), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the appointment of Saurabh Saha, M.D., Ph.D. to its Board of Directors. Dr. Saha is currently the Chief Executive Officer of Centessa Pharmaceuticals plc (NASDAQ:CNTA) ("Centessa") and brings more than 20 years of biopharmaceutical research and development expertise to the role.

    "We are pleased to welcome Dr. Saha to our Board of Directors," said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics. "His passion for discovering new cancer treatments, coupled with his track record of successful drug development and leadership across Biotech and Pharma, make him a compelling addition to the Board. In particular, we look forward to his leadership and expert guidance as we prepare to submit investigational new drug applications for our two lead programs next year. Dr. Saha's insights will be incredibly valuable as we advance our Precision Oncology 2.0 strategy, with the ultimate goal of delivering optimized and transformational therapies for larger populations of patients with cancer."

    "I'm incredibly excited to work alongside my fellow Board members and the executive team to advance the next frontier of precision medicines," said Dr. Saha. "In only a couple of years, Scorpion Therapeutics has advanced more than 15 programs through discovery across a wide variety of biologically validated targets, demonstrating the strength and versatility of the company's platform, as well as a genuine commitment to working with urgency and efficiency to benefit those in need. I look forward to sharing my expertise to help develop Scorpion's portfolio of product candidates so that we can meaningfully improve the lives of many more cancer patients facing significant unmet need."

    Prior to joining Centessa in 2021, Dr. Saha was Senior Vice President of Research & Development at Bristol Myers Squibb Company ("BMS"), where he led translational medicine across all therapeutic areas and stages of development and played a key role in the acquisition and integration of Celgene Corporation ("Celgene"), as well as the establishment of BMS' Research & Development headquarters in Cambridge, Massachusetts. Prior to that, Dr. Saha was a Venture Partner at Atlas Venture, where he held leadership positions with several portfolio biotech companies, including Chief Medical Officer of Synlogic, Inc. (NASDAQ:SYBX) and Chief Executive Officer of Delinia, Inc., until its sale to Celgene in early 2017. Before that, he established the translational research and development organization at BioMed Valley Discoveries, served as the Director and Head of the New Indications Discovery Unit at Novartis, and worked as a management consultant in the pharmaceutical practice at McKinsey & Company. Dr. Saha serves on the editorial boards of several prominent medical journals and has published over 100 combined peer-reviewed articles and patents (issued and pending). He is also an Associate Member and Global Clinical scholar at Harvard Medical School. Dr. Saha holds an M.D. and Ph.D. in cancer genetics from The Johns Hopkins School of Medicine. He completed the General Management Program at Harvard Business School, and he received an M.S. in Biophysics from the University of Oxford and a B.Sc. in Biochemistry from the California Institute of Technology.

    About Scorpion Therapeutics

    Scorpion Therapeutics is a pioneering oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of patients with cancer, a strategy Scorpion Therapeutics refers to as Precision Oncology 2.0. Scorpion Therapeutics has built a proprietary and fully integrated platform of the most advanced technologies across cancer biology, medicinal chemistry, and data sciences, with the goal of consistently and rapidly creating exquisitely selective small molecule compounds against an unprecedented spectrum of targets. Scorpion Therapeutics aims to leverage its platform to advance a broad pipeline of wholly owned, optimized compounds across three target categories: best-in-class molecules targeting validated oncogene targets; first-in-class molecules for previously undruggable targets; and first-in-class molecules for novel cancer targets. For more information, visit www.scorpiontx.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005231/en/

    Get the next $CNTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNTA
    $SYBX

    CompanyDatePrice TargetRatingAnalyst
    Centessa Pharmaceuticals plc
    $CNTA
    5/8/2025$30.00Buy
    Chardan Capital Markets
    Centessa Pharmaceuticals plc
    $CNTA
    3/31/2025$38.00Overweight
    Piper Sandler
    Centessa Pharmaceuticals plc
    $CNTA
    1/7/2025Buy
    TD Cowen
    Centessa Pharmaceuticals plc
    $CNTA
    9/20/2024$11.00 → $26.00Equal-Weight → Overweight
    Morgan Stanley
    Centessa Pharmaceuticals plc
    $CNTA
    9/19/2024$33.00Buy
    B. Riley Securities
    Centessa Pharmaceuticals plc
    $CNTA
    7/18/2024$14.00Outperform
    Oppenheimer
    Centessa Pharmaceuticals plc
    $CNTA
    11/15/2023$4.00 → $11.00Hold → Buy
    Jefferies
    Centessa Pharmaceuticals plc
    $CNTA
    10/26/2023$4.00 → $8.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $CNTA
    $SYBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

      Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025 ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) well underway and on track with data expected across all three indications in 2025 with first-in-class potential in NT2 and IHORX142 in IND-enabling studies for the treatment of neurological and neurodegenerative disorders; Clinical data in acutely sleep-deprived healthy volunteers planned for 2025ORX489 in IND-enabling studies for the treatment of neuropsychiatric disorders BOSTON and LONDON, March 24, 2025 (GLOBE NEWSWIRE) -- Cent

      3/24/25 7:00:49 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

      BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), will be presented in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial (CRYSTAL-1

      3/6/25 4:14:40 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

      BOSTON and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim SMID Cap Biotech Conference Date: February 6, 2025Fireside Chat: 1:00 PM ET Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference Date: February 12, 2025Fireside Chat: 10:40 AM ET Event: TD Cowen 45th Annual Health Care ConferenceDate: March 4, 2025Fireside Chat: 1:50 PM ET Event: Leerink Partners Global Healthcare ConferenceDate: March 11,

      1/28/25 8:00:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    $SYBX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Synlogic Inc.

      10-Q - SYNLOGIC, INC. (0001527599) (Filer)

      5/8/25 4:30:30 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Centessa Pharmaceuticals plc

      DEF 14A - Centessa Pharmaceuticals plc (0001847903) (Filer)

      5/6/25 9:00:14 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Synlogic Inc.

      10-K/A - SYNLOGIC, INC. (0001527599) (Filer)

      4/30/25 11:57:58 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    $SYBX
    Financials

    Live finance-specific insights

    See more
    • Synlogic Adopts Limited Duration Stockholders Rights Plan

      CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced that its Board of Directors (the "Board") has approved the adoption of a limited duration shareholder rights plan (the "Rights Plan") and authorized a dividend distribution of one right ("Right") for each outstanding share of common stock. The dividend distribution will be made on March 1, 2024, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on February 20, 2025. The Company also

      2/20/24 12:15:26 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

      SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentation at American Society of Hematology (ASH) Annual Meeting in December 2023 ORX750: Preclinical data supporting potential best-in-class profile for the treatment of narcolepsy and other sleep-wake disorders presented at World Sleep Congress; Advancing in IND-enabling studies; Clinical proof of concept data planned for 2024LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumors BOSTON and LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA

      11/13/23 4:05:10 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

      Enrollment and dosing ongoing in registrational study of SerpinPC for the treatment of hemophilia BEnrollment and dosing ongoing in Phase 1/2a Study of LB101, a PD-L1xCD47 LockBody® for the treatment of solid tumors IND-enabling activities advancing for ORX750, an oral selective orexin receptor 2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; Announces ORX750 preclinical data to be presented at World Sleep Congress in October 2023 Nominates second LockBody candidate, LB206, a conditionally bivalent PD-L1xCD3 bispecific monoclonal antibody BOSTON and LONDON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceuti

      8/14/23 7:00:30 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    $SYBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

      SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

      11/14/24 5:43:48 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Synlogic Inc.

      SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

      11/14/24 4:40:57 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Centessa Pharmaceuticals plc

      SC 13G/A - Centessa Pharmaceuticals plc (0001847903) (Subject)

      11/14/24 4:20:32 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    $SYBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Centessa Pharmaceuticals with a new price target

      Chardan Capital Markets initiated coverage of Centessa Pharmaceuticals with a rating of Buy and set a new price target of $30.00

      5/8/25 8:28:10 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Centessa Pharmaceuticals with a new price target

      Piper Sandler initiated coverage of Centessa Pharmaceuticals with a rating of Overweight and set a new price target of $38.00

      3/31/25 8:13:04 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Centessa Pharmaceuticals

      TD Cowen initiated coverage of Centessa Pharmaceuticals with a rating of Buy

      1/7/25 7:47:10 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    $SYBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel Hussain Iqbal J exercised 311 units of Ordinary Shares at a strike of $5.84 and sold $4,354 worth of Ordinary Shares (311 units at $14.00) (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      5/2/25 4:17:05 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Hussain Iqbal J exercised 5,689 units of Ordinary Shares at a strike of $5.84 and sold $79,658 worth of Ordinary Shares (5,689 units at $14.00) (SEC Form 4)

      4 - Centessa Pharmaceuticals plc (0001847903) (Issuer)

      4/29/25 4:58:03 PM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Shea Richard P was granted 15,000 shares, increasing direct ownership by 2,964% to 15,506 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/29/25 4:46:11 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTA
    $SYBX
    Leadership Updates

    Live Leadership Updates

    See more
    • Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

      BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.  "Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year," said Saurabh Saha MD

      1/8/25 7:05:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

      BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that John Crowley CPA, has been appointed Chief Financial Officer, and Gregory Weinhoff MD MBA, former Chief Financial Officer, has been appointed to the newly created role of Chief Business Officer, effective June 10, 2024. "With all three of our core programs in the clinic, we believe we have solidified a strong foundation and are poised for our next exciting chapter as a company. To best position Centessa for this pivotal time, we've added key new talen

      6/10/24 7:00:00 AM ET
      $CNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

      4/1/24 8:00:00 AM ET
      $LCTX
      $SYBX
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations